Literature DB >> 2458261

Tumor markers in non-malignant diseases.

Y Touitou1, A Bogdan.   

Abstract

This paper reviews the specificity of tumor markers recently introduced in clinical use, namely CA 19-9, CA 125, CA 15-3, CA 50 and SCC antigen. It appears that a large number of either biological conditions (age, sex, pregnancy, menstruation etc.), intoxication (smoking and alcohol addictions) or various non-malignant diseases do affect the serum levels of tumor markers. These data are of practical use in the interpretation of tumor marker determinations in the follow-up of cancer patients.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2458261     DOI： 10.1016/0277-5379(88)90113-7

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


  9 in total

1.  Increased CA 125 in tuberculous peritonitis.

Authors:  J Collazos
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

2.  Measurement of four tumor marker antigens in the sera of pregnant women.

Authors:  C D Cheli; D L Morris; I E Neaman; J Dai; W J Allard; K K Yeung
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

3.  The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Authors:  Maximilian Schöniger-Hekele; Christian Müller
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

4.  LETTER TO THE EDITOR: Is the Determination of CA-125 Serum Levels Useful for the Diagnosis of Pulmonary Tuberculosis?

Authors:  Julio Collazos
Journal:  Open Respir Med J       Date:  2010-03-19

5.  Reliability of tumor markers, chemokines, and metastasis-related molecules in serum.

Authors:  Faina Linkov; Yian Gu; Alan A Arslan; Mengling Liu; Roy E Shore; Lyudmila Velikokhatnaya; Karen L Koenig; Paolo Toniolo; Adele Marrangoni; Zoya Yurkovetsky; Anne Zeleniuch-Jacquotte; Anna E Lokshin
Journal:  Eur Cytokine Netw       Date:  2009-03       Impact factor: 2.737

6.  The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.

Authors:  Beyhan Omer; Sema Genc; Ozguc Takmaz; Ahmet Dirican; Zeynep Kusku-Kiraz; Sinan Berkman; Figen Gurdol
Journal:  Tumour Biol       Date:  2013-05-03

7.  Tumour marker antigens during menses and pregnancy.

Authors:  Y Touitou; Y Darbois; A Bogdan; A Auzéby; S Keusseoglou
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

8.  Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens.

Authors:  Y Touitou; A Bogdan; F Lévi; M Benavides; A Auzéby
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

9.  Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.

Authors:  O Nilsson; C Johansson; B Glimelius; B Persson; B Nørgaard-Pedersen; A Andrén-Sandberg; L Lindholm
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.